-- Lumea, a digital pathology tech company, has been honored with a 2025 Global Recognition Award for its contributions to cancer diagnostics through advanced technological solutions. The award acknowledges the organization's approach to digital pathology and its measurable impact on worldwide medical outcomes. Founded by pathologists Drs. Matthew O. Leavitt and Jared Szymanski in 2013, Lumea modified the landscape of diagnosis through its comprehensive digital pathology suite, which integrates both cutting-edge hardware and sophisticated software solutions.
Photo Courtesy of Lumea
The firm's solutions have enabled millions of clinical specimen diagnoses internationally, demonstrating significant market reach and establishing new standards in diagnostic accuracy. Lumea's core mission is to deliver practical, affordable digital laboratory solutions that empower specialists and fundamentally improve diagnostics throughout international health systems. The acknowledgment highlights the entity's focus on addressing essential challenges in analysis while maintaining high clinical performance standards.
Progressive Platforms Addressing Critical Medical Challenges
Traditional diagnostic methods rely on outdated processes, including physically transporting glass slides and samples in formaldehyde, creating damage and data loss risks. Some of Lumea’s products address these essential challenges through inventive design that changes how medical professionals handle and analyze tissue specimens. The company's approach recognizes that each biopsy holds crucial information, requiring optimal sample care from the point of collection through final diagnosis.
The BxBoard® system represents a fundamental improvement in tissue transport by replacing traditional biopsy transport bottles with modern solutions that reduce biohazard waste in histology laboratories by 136 percent and plastic waste by 83 percent. This system decreases formalin use by 89 percent, creating safer environments for medical professionals and reducing environmental impact within health facilities. This tech demonstrates how creative engineering can simultaneously address multiple challenges, improving clinical outcomes and workplace safety for health professionals. It also keeps needle-core biopsies flat, reducing linear variability on the final histologic slide.
The BxChip® is another significant advancement in tissue analysis technology that enhances tissue representation on glass slides by increasing tissue surface area by an average of 14.5 percent and biopsy core length by 31.8 percent. This improvement has resulted in a 9.3 percent average increase in accurate tumor detection rates, delivering measurable benefits in patient outcomes across global healthcare systems. The innovation shows how thoughtful engineering can directly translate into life-saving improvements in diagnostic accuracy.
Market Impact and Technological Progress: A Comprehensive Digital Pathology Suite
Lumea's comprehensive platform goes beyond hardware solutions, including a progressive laboratory viewer, image management system, and an integrated digital analysis platform that provides experts with remote diagnostic capabilities.
BxLink™ is Lumea's proprietary Laboratory Information System (LIS) and digital pathology suite, specifically designed as a "one-stop shop" for everything related to urology. It streamlines the entire workflow, from specimen accessioning and tracking to comprehensive case management and reporting. BxLink acts as a central hub, integrating all aspects of the digital pathology process, including image acquisition, viewing, analysis, and secure data storage. This integrated approach ensures seamless communication and efficiency for uropathologists, reducing manual errors and accelerating diagnostic turnaround times.
Lumea’s Viewer+™ is an innovative image management system (IMS) digital pathology plug-in designed for seamless integration with any existing LIS. This means that laboratories and pathology groups can leverage Lumea's advanced viewing and analysis capabilities without overhauling their current LIS infrastructure. Its flexibility ensures that Lumea's digital pathology features are accessible to a wider range of healthcare providers, enhancing clinical efficiencies and providing superior diagnostic support.
These tools enhance efficiency while providing access to machine learning and artificial intelligence technologies that support more accurate diagnoses. They also help address the urgent need for specialty expertise in rural, third-world, and other underserved areas around the world. The firm's approach to innovation emphasizes that genuine progress requires a complete rethinking of the entire diagnostic workflow to benefit every stakeholder, especially the patient.
Industry Honor and Future Growth
Alex Sterling from Global Recognition Awards highlighted the importance of the team's achievement in improving healthcare delivery. He states, "What distinguishes Lumea is its foundation as an entity created by medical professionals, for pathologists, ensuring that every improvement remains closely connected to real-world clinical needs rather than theoretical applications.” The comprehensive patent portfolio and demonstrated effect on over 2 million specimen diagnoses internationally represent a significant contribution to broad health progress.
The company continues to extend its reach with plans to release pre-analytical technology for breast biopsies, further increasing its influence on oncology diagnosis and treatment across multiple oncological specialties. Initially focused on prostate malignancy, which affects an estimated 288,300 new cases annually in the United States alone, Lumea has since expanded its solutions to address multiple tumor types. This expansion makes advanced diagnostic capabilities available to pathology groups of all sizes worldwide, ensuring that current technology reaches healthcare providers regardless of their institutional size or geographic location.
About Global Recognition Awards
Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have significantly contributed to their industry.
Contact Info:
Name: Alexander Sterling
Email: Send Email
Organization: Global Recognition Awards
Website: https://globalrecognitionawards.org
Release ID: 89165023
Google
RSS